Key Insights

Highlights

Treatment Research

3 treatments under study, led by Ngs Test For Ddr Alterations

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06820255Phase 4Recruiting

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Showing all 1 trials

Research Network

Common Treatments

  • Ngs Test For Ddr Alterations1
  • Platinum Gemcitabine1
  • Avelumab Firstline Maintenance1

Active Sponsors

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS1

Top Investigators

Related Conditions

  • Bladder Urothelial Transitional Cell Cancer Metastatic Or Unresectable1
  • Upper Tract Urothelial Cancer1

Activity Timeline